Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Cancer is one of the most fatal diseases with an increasing incidence and mortality all over the world. Thus, there is an urgent need for novel therapies targeting major cancer-related pathways. Nuclear factor-erythroid 2-related factor 2 (NRF2) and its major negative modulator Kelch-like ECH-associated protein 1 (KEAP1) are main players of the cellular defense mechanisms against internal and external cell stressors. However, NRF2/KEAP1 signaling pathway is dysregulated in various cancers, thus promoting tumor cell survival and metastasis. In the present review, we discuss the mechanisms of normal and deregulated NRF2 signaling pathway focusing on its cancer-related functions. We further explore activators and inhibitors of this pathway as cancer targeting drug candidates in order to provide an extensive background on the subject.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931 · cited 1×
“Low concentrations of NRF2 action caused augmented intracellular ROS, harmful effects to cellular molecules such as DNA, proteins, and lipids, as well as apoptosis [124].”
BackgroundItoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · cited 1×
“In addition, the basal expression level of ARE-mediated genes such as GCL, GST, HMOX1, NQO1, and UGT was found to be significantly suppressed in NRF2-deficient mice compared to the wild-type counterpart [11,35,36].”
BackgroundItoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 1×
“The Kelch/DGR domain functions as an NRF2 repressor, and it contains of six Kelch motif repeats, which are required for interaction with Neh2 domain of NRF2 [32].”
BackgroundCell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630 · cited 2×
“Therefore, mutations and modifications that escalate NRF2 activity are associated to cancer and chemo- and radioresistance developments [126].”
BackgroundTargeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Oxidative DNA damage: mechanisms, mutation, and disease
Cooke, M. S., Evans, M. D., Dizdaroglu, M., & Lunec, J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0752rev · Cited by 3,245 · cited 1×
“It was shown that NRF2 might stop DNA damage secondarily by decreasing the levels of ROS [100].”
BackgroundOncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 4×
“Depending on this, the oncogenic activation of K-RAS and B-RAF are sufficient to increase the NRF2 mRNA levels and support ROS detoxification in human cancer cells [84].”
BackgroundInfluentialDinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“To fully address the importance of NRF2 pathway in cancer, it is necessary to provide a description of its negative regulator KEAP1, that interacts with NRF2 to downmodulate its expression in cells and strictly control cellular homeostasis [8].”
Background
Cited by
Tkaczenko, H., & Kurhaluk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031098 · Cited by 80
Murphy, B., Latimer, C., Dobani, S., Pourshahidi, L. K., Fontana, M., Ternan, N. G., McDougall, G. J., Rowland, I., Pereira-Caro, G., Tuohy, K., et al. (2023) · doi:10.20944/preprints202308.0755.v1 · Cited by 1
Murphy, B. Ó., Latimer, C., Dobani, S., Pourshahidi, L. K., Fontana, M., Ternan, N. G., McDougall, G., Rowland, I., Pereira-Caro, G., Tuohy, K. M., et al. (2024) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2024.2397055
Metadata
- Authors
- Telkoparan-Akillilar, P., Panieri, E., Cevik, D., Suzen, S., & Saso, L.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-03-05
- Volume
- 26
- Issue
- 5
- Pages
- 1417
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3134984193
- Cited by
- 137
- References
- 31
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer. https://app.cochat.ai/papers/10.3390/molecules26051417
- The paper
- Telkoparan-Akillilar, P., Panieri, E., Cevik, D., Suzen, S., & Saso, L. (2021). Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer. Molecules. https://doi.org/10.3390/molecules26051417
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.